ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0410

Exploring Gene Expression Profile of Primary Central Nervous System Vasculitis

Carlo Salvarani1, Robert Brown2, Jonas Paludo2, Stefania Croci3, Stephen Ansell4, Caterina Giannini2, Joseph Parisi2, Kenneth Warrington2 and Gene Hunder2, 1Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, Reggio Emilia, Italy, 2Mayo Clinic, Rochester, MN, 3Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, 4Mayo Clinic, Rochester

Meeting: ACR Convergence 2020

Keywords: Brain, Inflammation, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Primary CNS vasculitis (PCNSV) is an uncommon and poorly understood disease that affects the brain and spinal cord. It includes heterogeneous  histopathological patterns,  clinical subsets,  outcomes, and response to treatment. PCNSV has also been associated with lymphoma suggesting an immunological paraneoplastic mechanism. The molecular hallmarks of PCNSV are still unknown. We  investigated the gene expression profile of granulomatous vasculitis (GV) including  with Hodgkin lymphoma (HL), lymphocytic vasculitis (LV) and amyloid β-related angiitis (ABRA).

Methods: Formalin fixed paraffin embedded (FFPE) brain biopsy samples were cut for histology and RNA extraction (n=3 GV with HL, n=1 GV without HL, n=5 LV, n=4 ABRA, n=4 normal brain). RNA-sequencing was performed using Illumina® Hiseq-4000 platform and the Illumina® TruSeq® Total-RNA library. Student’s t-test and false discovery rate (FDR) tests were performed for each of the differentially expressed transcripts. Ingenuity Pathway Analysis® was used for the pathway expression analysis.

Results: Samples clustered in three groups by unsupervised analysis of gene expression profile. Cluster 1 (C1) included all samples of GV with HL plus one of the samples of LV. Cluster 2 (C2) included all ABRA samples plus 4/5 LV samples and the GV not associated with HL. Normal brain samples clustered together in cluster 3 (C3). Results indicated that PCNSV has specific transcriptomes compared to normal brain and GV with HL have a distinct profile from the other types of PCNSV. Pathway analysis revealed upregulation of dendritic cell maturation and antigen processing, T helper type 1 lymphocyte activation and neuroinflammation in PCNSV versus normal brain. The comparison of the different kinds of PCNSV showed that GV expressed CD28 at lower levels than LV (FDR < 0.01) suggesting a lower activation of lymphocytes. The top differentially expressed genes between GV and ABRA were TRAJ13 and CD27 suggesting an expansion of naïve and memory T cells in GV. Finally, only one gene, namely CD163, was expressed at lower levels in LV than in ABRA (FDR < 0.05) suggesting a lower presence of macrophages or the presence of anti-inflammatory mediators.

Conclusion: RNA sequencing revealed pathways deregulated in PCNSV and genes differentially expressed between the different kinds of PCNSV increasing the knowledge on PCNSV pathogenesis. It also sugested that GV with HL has an distinct gene expression profile compared to other types of PCNSV.

Unsupervised Clustering by RNAseq: 3 clusters are clearly defined. No cases clustered with normal samples


Disclosure: C. Salvarani, None; R. Brown, None; J. Paludo, None; S. Croci, None; S. Ansell, None; C. Giannini, None; J. Parisi, None; K. Warrington, Lilly, 2, Kiniksa, 2; G. Hunder, None.

To cite this abstract in AMA style:

Salvarani C, Brown R, Paludo J, Croci S, Ansell S, Giannini C, Parisi J, Warrington K, Hunder G. Exploring Gene Expression Profile of Primary Central Nervous System Vasculitis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/exploring-gene-expression-profile-of-primary-central-nervous-system-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exploring-gene-expression-profile-of-primary-central-nervous-system-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology